Nikki A Martin, Sue J. Friedman, Claire Saxton, Ronit Varden, Stacie Lindsey, Erica Kuhn,Janine Guglielmina, Reese Garcia, Cassadie Moravek, Deborah A Zajchowski, Andrea K. Miyahira, Denisse Montoya, Christine Verini,Janelle Schrag, Victor Gonzalez, Gillian Hooker, Cynthia Bens, Beth Davison, Marcia K. Horn
LUNGevity Foundation, Bethesda, MD; FORCE-Facing our Risk of Cancer Empowered, Tampa, FL; Cancer Support Community, Research and Training Institute, Washington, DC; Colorectal Cancer Alliance, Washington, DC; The Cholangiocarcinoma Foundation, Salt Lake City, UT; Susan G. Kamen, Dallas, TX; Living Beyond Breast Cancer, Bala Cynwyd, PA; Fight Colorectal Cancer, Springfield, MO; Pancreatic Cancer Action Network, Manhattan Beach, CA; One Consult Svcs, San Francisco, CA; Prostate Cancer Foundation, Santa Monica, CA; The Life Raft Group, Wayne, NJ; CancerCare, New York, NY; Association of Community Cancer Centers, Rockville, MD; Lymphoma Research Foundation, New York, NY; Concert Genetics, Franklin, TN; Personalized Medicine Coalition, Washington DC, DC; LLS, St Augustine, FL; lnt'I Cancer Advocacy Network, Phoenix, AZ
Biomarker testing has advanced precision medicine in cancer. However, not all eligible patients benefit from biomarker-driven therapies due to suboptimal testing rates. A working group of 20 patient advocacy groups representing solid/hematologic malignancies, three professional societies, and 18 pharmaceutical and diagnostics companies identified patient confusion inconsistent testing terms as a possible contributing factor to biomarker testing underutilization. The group aimed to address patients' confusion by identifying and adopting consistent, plain language terms for biomarker and germline genetic testing that are applicable across cancer types.